Singapore markets closed

Verona Pharma plc (VRNA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
16.25-0.25 (-1.53%)
As of 12:30PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close16.50
Open16.60
Bid16.18 x 200
Ask20.85 x 200
Day's range16.13 - 16.73
52-week range11.83 - 23.81
Volume107,033
Avg. volume522,985
Market cap1.316B
Beta (5Y monthly)0.42
PE ratio (TTM)N/A
EPS (TTM)-0.72
Earnings date07 May 2024 - 11 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est33.14
  • GlobeNewswire

    Andrew Fisher Joins Verona Pharma as General Counsel

    LONDON and RALEIGH, N.C., March 04, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces Mr. Andrew Fisher has today joined the Company as General Counsel, and member of the Executive Management Team. Mr. Fisher is an accomplished lawyer with more than 25 years of experience in the life sciences industry. He brings a wealth of legal and strategic expertise supporting global, pre-clinical and clinical development, manufacturing and commercializat

  • Insider Monkey

    Verona Pharma plc (NASDAQ:VRNA) Q4 2023 Earnings Call Transcript

    Verona Pharma plc (NASDAQ:VRNA) Q4 2023 Earnings Call Transcript February 29, 2024 Verona Pharma plc beats earnings expectations. Reported EPS is $-0.18, expectations were $-0.23. VRNA isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to Verona Pharma’s Fourth Quarter […]

  • GuruFocus.com

    Verona Pharma PLC Reports Fourth Quarter and Full Year 2023 Financial Results

    VRNA Prepares for Potential Commercial Launch with Strong Financial Position